Our results showed that selected patients with lung cancer brain metastases and EGFR mutations or ALK translocations derived clinical benefit from Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel treatment despite high toxicity rates. Here, ALK is linked to lung carcinoma.